Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Cogent Biosciences (COGT) Operating Expenses (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of Operating Expenses data on record, last reported at $25.6 million in Q4 2021.

  • For Q4 2021, Operating Expenses rose 123.81% year-over-year to $25.6 million; the TTM value through Dec 2021 reached $75.6 million, down 16.12%, while the annual FY2025 figure was $333.4 million, 20.81% up from the prior year.
  • Operating Expenses reached $25.6 million in Q4 2021 per COGT's latest filing, up from $19.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $57.5 million in Q3 2020 and bottomed at $7.9 million in Q2 2020.
  • Average Operating Expenses over 4 years is $16.6 million, with a median of $13.1 million recorded in 2019.
  • Peak YoY movement for Operating Expenses: skyrocketed 340.49% in 2020, then crashed 65.54% in 2021.
  • A 4-year view of Operating Expenses shows it stood at $12.8 million in 2018, then grew by 1.87% to $13.0 million in 2019, then fell by 12.2% to $11.5 million in 2020, then skyrocketed by 123.81% to $25.6 million in 2021.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $25.6 million in Q4 2021, $19.8 million in Q3 2021, and $17.3 million in Q2 2021.